SYRE
Aeglea BioTherapeutics Inc

2,054
Mkt Cap
$2.84B
Volume
681,084.00
52W High
$37.98
52W Low
$10.91
PE Ratio
-16.82
SYRE Fundamentals
Price
$35.95
Prev Close
$36.63
Open
$36.39
50D MA
$33.01
Beta
1.71
Avg. Volume
616,557.10
EPS (Annual)
-$3.18
P/B
4.90
Rev/Employee
$0.00
$647.54
Loading...
Loading...
News
all
press releases
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 8.5% - Should You Buy?
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Up 8.5% - Here's What Happened...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Spyre Therapeutics, Inc. $SYRE Shares Acquired by Candriam S.C.A.
Candriam S.C.A. boosted its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 64.4% in the third quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·7d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High - Here's What Happened
Spyre Therapeutics (NASDAQ:SYRE) Hits New 12-Month High - Still a Buy...
MarketBeat·8d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $492,000.00 in Stock
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an...
MarketBeat·13d ago
News Placeholder
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Sees Significant Decrease in Short Interest
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 10,069,741 shares, a...
MarketBeat·15d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research
BTIG Research reissued a "buy" rating and set a $70.00 target price on shares of Spyre Therapeutics in a report on Friday...
MarketBeat·1mo ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% Higher - What's Next?
Spyre Therapeutics (NASDAQ:SYRE) Trading 7.7% Higher - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $460,200.00 in Stock
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction dated Friday, January 2nd. The stock was sold at an average...
MarketBeat·1mo ago
News Placeholder
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the firm's stock in a transaction on Friday, January 2nd. The shares were sold at an average price of...
MarketBeat·1mo ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5% - Time to Sell?
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5% - What's Next...
MarketBeat·2mo ago
<
1
2
...
>

Latest SYRE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.